Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol

Ana García-Robles, Ana Gimeno Navarro, María Del Mar Serrano Martín, María José Párraga Quiles, Anna Parra Llorca, José Luis Poveda-Andrés, Máximo Vento Torres, Marta Aguar Carrascosa, Ana García-Robles, Ana Gimeno Navarro, María Del Mar Serrano Martín, María José Párraga Quiles, Anna Parra Llorca, José Luis Poveda-Andrés, Máximo Vento Torres, Marta Aguar Carrascosa

Abstract

Background: Currently, the first line treatment of persistent ductus arteriosus (PDA) is either indomethacin or ibuprofen. However, the potentially life-threatening side effects associated to their use have prompted physicians to look for alternative options. The incorporation of paracetamol as an alternative to ibuprofen in the management of PDA is still based on insufficient clinical evidence. Hence, more clinical trials are needed to establish a therapeutic role for paracetamol in the management of PDA that take into consideration short- and long-term safety and efficacy outcomes. Study Design: This is a non-inferiority, randomized, multicenter, double-blinded study to evaluate the efficacy, and safety of intravenous (IV) paracetamol vs. IV ibuprofen (standard treatment) for PDA in preterm patients with a gestational age ≤ 30 weeks. At baseline, patients will be randomized (1:1) to treatment with paracetamol or ibuprofen. The primary endpoint is closure of the ductus after the first treatment course. Secondary endpoints are related to effectiveness (need for a second treatment course, rescue treatment, reopening rate, time to definitive closure, need for surgical ligation), safety (early and long-term complications), pharmacokinetics, and pharmacodynamics, pharmacogenetics, pharmacoeconomics, and genotoxicity. Long-term follow-up to 24 months of corrected postnatal age will be performed using Bayley III neurodevelopmental scale. Trial Registration: ClinicalTrials.gov Identifier: NCT04037514. EudraCT: 2015-003177-14.

Keywords: ductus; efficacy; paracetamol; pharmacogenetics; pharmacokinetics; safety.

Copyright © 2020 García-Robles, Gimeno Navarro, Serrano Martín, Párraga Quiles, Parra Llorca, Poveda-Andrés, Vento Torres and Aguar Carrascosa.

Figures

Figure 1
Figure 1
Diagram of study. (A) Birth; (B) diagnostic and randomization; The PARACETAMOL group will receive IV doses of 15 mg/kg administered every 6 h for 3 days (maximum two courses = 6 days of treatment). The IBUPROFEN group (control group) will receive an initial dose of IV 10 mg/kg followed by 5 mg/kg at 24 and 48 h (the three doses are considered a treatment course, maximum two courses). (C) Surgical close. (D) FOLLOW-UP: 40 weeks, 12 months, and 24 months.

References

    1. González MDR, Guzmán EG, Quiles MJP, Tejero MA, Cabañas JMG. Ductus arterioso persistente. Protoc Diagnóstico Ter AEP Neonatol. (2008) 353–361.
    1. Schneider DJ, Moore JW. Patent ductus arteriosus. Circulation. (2006) 114:1873–82. 10.1161/CIRCULATIONAHA.105.592063
    1. Wyllie J. Treatment of patent ductus arteriosus. Semin Neonatol SN. (2003) 8:425–32. 10.1016/S1084-2756(03)00121-0
    1. Benitz WE, Committee on Fetus and Newborn . Patent ductus arteriosus in preterm infants. Pediatrics. (2016) 137:e20153730. 10.1542/peds.2015-3730
    1. Bart Van Overmeire SC. The pharmacologic closure of the patent ductus arteriosus. Semin Fetal Amp Neonatal Med. (2005) 10:177–84. 10.1016/j.siny.2004.10.003
    1. Vanhaesebrouck S, Zonnenberg I, Vandervoort P, Bruneel E, Van Hoestenberghe M-R, Theyskens C. Conservative treatment for patent ductus arteriosus in the preterm. Arch Dis Child Fetal Neonatal Ed. (2007) 92:F244–7. 10.1136/adc.2006.104596
    1. Bagheri MM, Niknafs P, Sabsevari F, Torabi MH, Bahman Bijari B, Noroozi E, et al. . Comparison of oral acetaminophen versus ibuprofen in premature infants with patent ductus arteriosus. Iran J Pediatr. (2016) 26:3975. 10.5812/ijp.3975
    1. Fanos V, Marcialis MA, Bassareo PP, Antonucci R, Zaffanello M, Dessì A, et al. . Renal safety of non steroidal anti inflammatory drugs (NSAIDs) in the pharmacologic treatment of patent ductus arteriosus. J Matern-Fetal Neonatal Med. (2011) 24(Suppl.1):50–52. 10.3109/14767058.2011.607593
    1. Demirel G, Erdeve O, Dilmen U. Pharmacological management of PDA: oral versus intravenous medications. Curr Clin Pharmacol. (2012) 7:263–70. 10.2174/157488412803305830
    1. Lago P, Bettiol T, Salvadori S, Pitassi I, Vianello A, Chiandetti L, et al. . Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: a randomised controlled trial. Eur J Pediatr. (2002) 161:202–7. 10.1007/s00431-002-0915-y
    1. Patel J, Roberts I, Azzopardi D, Hamilton P, Edwards AD. Randomized double-blind controlled trial comparing the effects of ibuprofen with indomethacin on cerebral hemodynamics in preterm infants with patent ductus arteriosus. Pediatr Res. (2000) 47:36–42. 10.1203/00006450-200001000-00009
    1. Hammerman C, Bin-Nun A, Markovitch E, Schimmel MS, Kaplan M, Fink D. Ductal closure with paracetamol: a surprising new approach to patent ductus arteriosus treatment. Pediatrics. (2011) 128:e1618–21. 10.1542/peds.2011-0359
    1. Dang D, Wang D, Zhang C, Zhou W, Zhou Q, Wu H. Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial. PLoS ONE. (2013) 8:e77888. 10.1371/journal.pone.0077888
    1. Oncel MY, Yurttutan S, Erdeve O, Uras N, Altug N, Oguz SS, et al. . Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. J Pediatr. (2014) 164:510–14.e1. 10.1016/j.jpeds.2013.11.008
    1. Kessel I, Waisman D, Lavie-Nevo K, Golzman M, Lorber A, Rotschild A. Paracetamol effectiveness, safety and blood level monitoring during patent ductus arteriosus closure: a case series. J Matern Fetal Neonatal Med. (2014) 27:1719–21. 10.3109/14767058.2013.871630
    1. El-Khuffash A, Jain A, Corcoran D, Shah PS, Hooper CW, Brown N, et al. . Efficacy of paracetamol on patent ductus arteriosus closure may be dose dependent: evidence from human and murine studies. Pediatr Res. (2014) 76:238–44. 10.1038/pr.2014.82
    1. Alan S, Kahvecioglu D, Erdeve O, Atasay B, Arsan S. Is paracetamol a useful treatment for ibuprofen-resistant patent ductus arteriosus? Neonatology. (2013) 104:168–9. 10.1159/000352068
    1. Tekgündüz KS, Ceviz N, Caner I, Olgun H, Demirelli Y, Yolcu C, et al. . Intravenous paracetamol with a lower dose is also effective for the treatment of patent ductus arteriosus in pre-term infants. Cardiol Young. (2014) 25:1060–4. 10.1017/S1047951114001577
    1. Oncel MY, Yurttutan S, Uras N, Altug N, Ozdemir R, Ekmen S, et al. . An alternative drug (paracetamol) in the management of patent ductus arteriosus in ibuprofen-resistant or contraindicated preterm infants. Arch Dis Child Fetal Neonatal Ed. (2012) 98:F94. 10.1136/archdischild-2012-302044
    1. Jasani B, Kabra N, Nanavati R. Oral paracetamol in treatment of closure of patent ductus arteriosus in preterm neonates. J Postgrad Med. (2013) 59:312–4. 10.4103/0022-3859.123164
    1. Sinha R, Negi V, Dalal SS. An interesting observation of PDA closure with oral paracetamol in preterm neonates. J Clin Neonatol. (2013) 2:30–32. 10.4103/2249-4847.109245
    1. Roofthooft DW, van Beynum IM, de Klerk JC, van Dijk M, van den Anker JN, Reiss IK, et al. . Limited effects of intravenous paracetamol on patent ductus arteriosus in very low birth weight infants with contraindications for ibuprofen or after ibuprofen failure Eur J Pediatr. (2015) 174:1433–40. 10.1007/s00431-015-2541-5
    1. Ozdemir OMA, Dogan M, Küçüktaşçi K, Ergin H, Sahin O. Paracetamol therapy for patent ductus arteriosus in premature infants: a chance before surgical ligation. Pediatr Cardiol. (2014) 35:276–9. 10.1007/s00246-013-0770-9
    1. Nadir E, Kassem E, Foldi S, Hochberg A, Feldman M. Paracetamol treatment of patent ductus arteriosus in preterm infants. J Perinatol Off J Calif Perinat Assoc. (2014) 34:748–9. 10.1038/jp.2014.96
    1. Pérez Domínguez ME, Rivero Rodríguez S, García-Muñoz Rodrigo F. El paracetamol podría ser útil en el tratamiento del ductus arterioso persistente en el recién nacido de muy bajo peso. An Pediatría. (2015) 82:362–3. 10.1016/j.anpedi.2014.07.018
    1. Sancak S, Gokmen Yildirim T, Topcuoglu S, Yavuz T, Karatekin G, Ovali F. Oral versus intravenous paracetamol: which is better in closure of patent ductus arteriosus in very low birth weight infants? J Matern Fetal Neonatal Med. (2016) 29:135–9. 10.3109/14767058.2014.989829
    1. Yang B, Gao X, Ren Y, Wang Y, Zhang Q. Oral paracetamol vs. oral ibuprofen in the treatment of symptomatic patent ductus arteriosus in premature infants: a randomized controlled trial. Exp Ther Med. (2016) 12:2531–6. 10.3892/etm.2016.3676
    1. Dash SK, Kabra NS, Avasthi BS, Sharma SR, Padhi P, Ahmed J. Enteral paracetamol or intravenous indomethacin for closure of patent ductus arteriosus in preterm neonates: a randomized controlled trial. Indian Pediatr. (2015) 52:573–8. 10.1007/s13312-015-0677-z
    1. Al-lawama M, Alammori I, Abdelghani T, Badran E. Oral paracetamol versus oral ibuprofen for treatment of patent ductus arteriosus. J Int Med Res. (2018) 46:811–18. 10.1177/0300060517722698
    1. El-Mashad AE-R, El-Mahdy H, El Amrousy D, Elgendy M. Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates. Eur J Pediatr. (2017) 176:233–40. 10.1007/s00431-016-2830-7
    1. Kumar A, Gosavi RS, Sundaram V, Oleti TP, Krishnan A, Kiran S, et al. . Oral paracetamol vs oral ibuprofen in patent ductus arteriosus: a randomized, controlled, noninferiority trial. J. Pediatr. (2020) 222:79–84. 10.1016/j.jpeds.2020.01.058
    1. Terrin G, Conte F, Oncel MY, Scipione A, McNamara PJ, Simons S, et al. . Paracetamol for the treatment of patent ductus arteriosus in preterm neonates: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed. (2016) 101:F127–36. 10.1136/archdischild-2014-307312
    1. Huang X, Wang F, Wang K. Paracetamol versus ibuprofen for the treatment of patent ductus arteriosus in preterm neonates: a meta-analysis of randomized controlled trials. J Matern-Fetal Neonatal Med. (2018) 31:2216–22. 10.1080/14767058.2017.1338263
    1. Jasani B, Weisz DE, McNamara PJ. Evidence-based use of acetaminophen for hemodynamically significant ductus arteriosus in preterm infants. Semin Perinatol. (2018) 42:243–52. 10.1053/j.semperi.2018.05.007
    1. Ohlsson A, Shah PS. Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants. Cochrane Database Syst Rev. (2018) 4:CD010061. 10.1002/14651858.CD010061.pub3
    1. Sallmon H, Koehne P, Hansmann G. Recent advances in the treatment of preterm newborn infants with patent ductus arteriosus. Clin Perinatol. (2016) 43:113–29. 10.1016/j.clp.2015.11.008
    1. Oncel MY, Yurttutan S, Degirmencioglu H, Uras N, Altug N, Erdeve O, et al. . Intravenous paracetamol treatment in the management of patent ductus arteriosus in extremely low birth weight infants. Neonatology. (2013) 103:166–9. 10.1159/000345337
    1. Ramos-Díaz R, Gutiérrez-Nicolás F, Nazco-Casariego GJ, González-Perera I, Pérez-Pérez JA. Validation of a fast and low-cost alkaline lysis method for gDNA extraction in a pharmacogenetic context. Cancer Chemother Pharmacol. (2015) 75:1095–8. 10.1007/s00280-015-2729-4
    1. Mlinarić A, Horvat M, Šupak Smolčić V. Dealing with the positive publication bias: Why you should really publish your negative results. Biochem Medica. (2017) 27:030201. 10.11613/BM.2017.030201
    1. Kahan BC, Rehal S, Cro S. Risk of selection bias in randomised trials. Trials. (2015) 16:405. 10.1186/s13063-015-0920-x
    1. Cuzzolin L, Bardanzellu F, Fanos V. The dark side of ibuprofen in the treatment of patent ductus arteriosus: could paracetamol be the solution? Expert Opin Drug Metab Toxicol. (2018) 14:855–68. 10.1080/17425255.2018.1492550
    1. Kumar A, Sundaram V, Yadav R, Oleti TP, Murki S, Krishna A, et al. . Oral paracetamol versus oral ibuprofen for closure of haemodynamically significant patent ductus arteriosus in preterm neonates (<32 weeks): a blinded, randomised, active-controlled, non-inferiority trial. BMJ Paediatr Open. (2017) 1:e000143. 10.1136/bmjpo-2017-000143
    1. Abdel-Hady H, Nasef N, Shabaan AE, Nour I. Patent ductus arteriosus in preterm infants: do we have the right answers? BioMed Res Int. (2013) 2013:676192. 10.1155/2013/676192
    1. Anker JN van den, Allegaert K. Acetaminophen to prevent symptomatic patent ductus arteriosus: another drug bites the dust? J Pediatr. (2016) 177:7–9. 10.1016/j.jpeds.2016.06.034
    1. Bardanzellu F, Neroni P, Dessì A, Fanos V. Paracetamol in patent ductus arteriosus treatment: efficacious and safe? BioMed Res Int. (2017) 2017:1438038. 10.1155/2017/1438038
    1. Gillam-Krakauer M, Reese J. Diagnosis and management of patent ductus arteriosus. NeoRev. (2018) 19:e394–402. 10.1542/neo.19-7-e394
    1. McNamara PJ, Sehgal A. Towards rational management of the patent ductus arteriosus: the need for disease staging. Arch Dis Child Fetal Neonatal Ed. (2007) 92:F424–7. 10.1136/adc.2007.118117
    1. Pacifici GM, Allegaert K. Clinical pharmacology of paracetamol in neonates: a review. Curr Ther Res. (2015) 77:24–30. 10.1016/j.curtheres.2014.12.001
    1. AEMPS . Ficha técnica-Paracetamol Combino Pharm 10 mg/ml solución para perfusión EFG. (2010). Available online at: (accessed July 14, 2018).
    1. Yurttutan S, Oncel MY, Arayici S, Uras N, Altug N, Erdeve O, et al. . A different first-choice drug in the medical management of patent ductus arteriosus: oral paracetamol. J Matern Fetal Neonatal Med. (2012) 26:825–7. 10.3109/14767058.2012.755162
    1. Bin-Nun A, Fink D, Mimouni FB, Algur N, Hammerman C. Paracetamol serum concentrations in neonates treated enterally for ductal closure: a pilot study. J Pediatr. (2018) 198:304–7. 10.1016/j.jpeds.2018.01.024
    1. Ferguson JM. Pharmacotherapy for patent ductus arteriosus closure. Congenit Heart Dis. (2019) 14:52–56. 10.1111/chd.12715
    1. Hammerman C, Mimouni FB, Bin-Nun A. A systematic review of paracetamol closure of patent ductus arteriosus: ready for prime time? Pediat Adol Med. (2015) 18:70–82. 10.1159/000365029
    1. Singla NK, Parulan C, Samson R, Hutchinson J, Bushnell R, Beja EG, et al. . Plasma and cerebrospinal fluid pharmacokinetic parameters after single-dose administration of intravenous, oral, or rectal acetaminophen. Pain Pract. (2012) 12:523–32. 10.1111/j.1533-2500.2012.00556.x
    1. Viña J, Vento M, García-Sala F, Puertes IR, Gascó E, Sastre J, et al. . L-cysteine and glutathione metabolism are impaired in premature infants due to cystathionase deficiency. Am J Clin Nutr. (1995) 61:1067–69. 10.1093/ajcn/61.5.1067

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi